scholarly journals A Decision Aid for Women Considering Neoadjuvant Systemic Therapy for Operable Invasive Breast Cancer: Development and Protocol of a Phase II Evaluation Study (ANZ1301 DOMINO)

2016 ◽  
Vol 5 (2) ◽  
pp. e88 ◽  
Author(s):  
Nicholas Zdenkowski ◽  
Phyllis Butow ◽  
Elizabeth Hutchings ◽  
Charles Douglas ◽  
Joseph R Coll ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Phase Ii ◽  
Invasive Breast Cancer ◽  
Systemic Therapy ◽  
Decision Aid ◽  
Evaluation Study ◽  
Cancer Development ◽  
Breast Cancer Development ◽  
Neoadjuvant Systemic Therapy

scholarly journals Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials

2017 ◽  
Vol 24 (10) ◽  
pp. 2855-2862 ◽  
Author(s):  
Henry M. Kuerer ◽  
Marie-Jeanne T. F. D. Vrancken Peeters ◽  
Daniel W. Rea ◽  
Mark Basik ◽  
Jennifer De Los Santos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Invasive Breast Cancer ◽  
Systemic Therapy ◽  
Nonoperative Management ◽  
Conceptual Basis ◽  
Neoadjuvant Systemic Therapy

scholarly journals Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) Model for Breast Cancer Risk Prediction in Women With Atypical Hyperplasia

2010 ◽  
Vol 28 (22) ◽  
pp. 3591-3596 ◽  
Author(s):  
Judy C. Boughey ◽  
Lynn C. Hartmann ◽  
Stephanie S. Anderson ◽  
Amy C. Degnim ◽  
Robert A. Vierkant ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Invasive Breast Cancer ◽  
Atypical Hyperplasia ◽  
Cancer Development ◽  
Cancer Risk Assessment ◽  
Individual Risk ◽  
Breast Cancer Development ◽  
Breast Cancer Risk Assessment

Purpose Accurate breast cancer risk assessment is vital to personalize screening and risk reduction strategies. Women with atypical hyperplasia have a four-fold higher risk of breast cancer. We evaluated the performance of the Tyrer-Cuzick model, which was designed to predict 10-year risk of breast cancer development, in a well-defined cohort of women with atypia. Patients and Methods The Mayo Benign Breast Disease cohort includes 9,376 women who had a benign breast biopsy between 1967 and 1991. Among those, 331 women with atypia were identified by our study pathologists. Risk factor data for the Tyrer-Cuzick model were collated for each woman and used to predict individual risk of developing invasive breast cancer within 10 years. Results Over a median follow-up of 14.6 years, 64 (19%) of the 331 women developed invasive breast cancer. In the first 10 years after biopsy, 31 women developed invasive breast cancer whereas the Tyrer-Cuzick model predicted 58.9. The observed-to-predicted ratio was 0.53 (95% CI, 0.37 to 0.75). The concordance statistic was 0.540, revealing that the Tyrer-Cuzick model did not accurately distinguish, on an individual level, between women who developed invasive breast cancer and those who did not. Conclusion The Tyrer-Cuzick model significantly overestimated risk of breast cancer for women with atypia, and individual risk estimates showed poor concordance between predicted risk and invasive breast cancer development. Thus, we cannot recommend the use of the Tyrer-Cuzick model to predict 10-year breast cancer risk in women with atypical hyperplasia.

scholarly journals Exploring women's experiences with a decision aid for neoadjuvant systemic therapy for operable breast cancer

2017 ◽  
Vol 1 (1) ◽  
pp. e13 ◽  
Author(s):  
Anne Herrmann ◽  
Frances Boyle ◽  
Phyllis Butow ◽  
Alix E. Hall ◽  
Nicholas Zdenkowski
Keyword(s):  
Breast Cancer ◽  
Systemic Therapy ◽  
Decision Aid ◽  
Operable Breast Cancer ◽  
Women’S Experiences ◽  
Women's Experiences ◽  
Neoadjuvant Systemic Therapy

scholarly journals Primary results of a study to evaluate a decision aid for women offered neoadjuvant systemic therapy for breast cancer

2017 ◽  
Vol 28 ◽  
pp. v509
Author(s):  
N. Zdenkowski ◽  
P. Butow ◽  
A.J. Spillane ◽  
C. Douglas ◽  
C. Beckmore ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systemic Therapy ◽  
Decision Aid ◽  
Neoadjuvant Systemic Therapy

scholarly journals Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer

2015 ◽  
Vol 15 (5) ◽  
pp. 325-331 ◽  
Author(s):  
Ana M. Gonzalez-Angulo ◽  
Xiudong Lei ◽  
Richardo H. Alvarez ◽  
Majorie C. Green ◽  
James L. Murray ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Phase Ii ◽  
Systemic Therapy ◽  
Residual Disease ◽  
Randomized Study ◽  
Neoadjuvant Systemic Therapy
Sign in / Sign up

Export Citation Format

Share Document